Dimapur News Desk

Non-muscle Invasive Bladder Cancer (NMIBC) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Non-muscle Invasive Bladder Cancer (NMIBC) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight

June 04
00:15 2021
Non-muscle Invasive Bladder Cancer (NMIBC) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Non-muscle Invasive Bladder Cancer (NMIBC)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non-muscle Invasive Bladder Cancer (NMIBC), historical and forecasted epidemiology as well as the Non-muscle Invasive Bladder Cancer (NMIBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Non-muscle Invasive Bladder Cancer (NMIBC)-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Non-muscle Invasive Bladder Cancer (NMIBC)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non-muscle Invasive Bladder Cancer (NMIBC), historical and forecasted epidemiology as well as the Non-muscle Invasive Bladder Cancer (NMIBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. The total diagnosed prevalent population of NMIBC in the seven major market ranges was 533,263 in 2017, which will increase for the study period i.e., 2017–2030.

  2. In 2017, the diagnosed prevalent population of low-grade NMIBC patients was 136,822 and high-grade NMIBC patients were 76,962 in the US, which is anticipated to increase in the forecast period.

  3. In Japan, the diagnosed prevalent population of NMIBC was 74,691 in 2017.

Key benefits of the report:

1.The Non-muscle Invasive Bladder Cancer (NMIBC) market report covers a descriptive overview and comprehensive insight of the Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology and Non-muscle Invasive Bladder Cancer (NMIBC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Non-muscle Invasive Bladder Cancer (NMIBC) market report provides insights into the current and emerging therapies.

3.Non-muscle Invasive Bladder Cancer (NMIBC) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Non-muscle Invasive Bladder Cancer (NMIBC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Non-muscle Invasive Bladder Cancer (NMIBC) market.

Request for sample pages: https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market

Non-muscle Invasive Bladder Cancer (NMIBC): Overview

Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. Bladder cancer is the 6th most common cancer in the United States. Nearly 84,000 people will be diagnosed in the United States with bladder cancer in 2021.

The key players involved in the Non-muscle Invasive Bladder Cancer (NMIBC) Market:

 

  1. FKD Therapies Oy/ Ferring Pharmaceuticals

  2. Merck

  3. ViventiaBio/Sesen Bio

  4. ImmunityBio/ Altor Biosciences

  5. Theralase

  6. CG Oncology

  7. Seattle Genetics

The launch of the emerging therapies is expected to significantly impact the  Non-muscle Invasive Bladder Cancer (NMIBC) treatment scenario in the upcoming years:-

Drug covered

  1. Adstiladrin

  2. Keytruda

  3. Vicinium

  4. N-803 (ALT-803) 

  5. TLD-1433

  6. CG0070

  7. Padcev

Request a free sample report @https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Non-muscle Invasive Bladder Cancer (NMIBC) Patient Share (%) Overview at a Glance

5. Non-muscle Invasive Bladder Cancer (NMIBC) Market Overview at a Glance

6. Non-muscle Invasive Bladder Cancer (NMIBC) Disease Background and Overview

7. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-muscle Invasive Bladder Cancer (NMIBC) 

9. Non-muscle Invasive Bladder Cancer (NMIBC) Current Treatment and Medical Practices

10. Unmet Needs

11. Non-muscle Invasive Bladder Cancer (NMIBC) Emerging Therapies

12. Non-muscle Invasive Bladder Cancer (NMIBC) Market Outlook

13. Country-Wise Non-muscle Invasive Bladder Cancer (NMIBC) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Non-muscle Invasive Bladder Cancer (NMIBC) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Non-muscle Invasive Bladder Cancer (NMIBC)-Epidemiology Forecast to 2030

DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Categories